Mepolizumab

Details

Files

Generic Name:

Mepolizumab

Project Status:

Complete

Therapeutic Area:

Eosinophilic Granulomatosis with Polyangiitis

Call for patient/clinician input open:

December 21, 2023

Brand Name:

N/A

Project Line:

Reimbursement Review

Project Number:

SX0839-000

Call for patient/clinician input closed:

February 20, 2024

Biosimilar:

Manufacturer Requested Reimbursement Criteria¹:

N/A

Submission Type:

Non-sponsored Submission

Fee Schedule:

Pending

Indications:

Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Recommendation Type:

Reimburse with clinical criteria and/or conditions

Final Recommendation:

November 25, 2024

The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.

Key Milestones²
Milestones title	Date
Submission received	19-Dec-23
Review initiated	20-Dec-23
Expert committee meeting (initial)	04-Jul-24
Draft recommendation posted for stakeholder feedback	01-Aug-24
End of feedback period	16-Aug-24
Clarification: - Reconsideration: minor revisions requested by drug programs - Request for reconsideration accepted
Final recommendation posted	-
CADTH review report(s) posted	10-Sep-24